MX2016014504A - Animales c5 y c3 humanizados. - Google Patents
Animales c5 y c3 humanizados.Info
- Publication number
- MX2016014504A MX2016014504A MX2016014504A MX2016014504A MX2016014504A MX 2016014504 A MX2016014504 A MX 2016014504A MX 2016014504 A MX2016014504 A MX 2016014504A MX 2016014504 A MX2016014504 A MX 2016014504A MX 2016014504 A MX2016014504 A MX 2016014504A
- Authority
- MX
- Mexico
- Prior art keywords
- human
- humanized
- animals
- gene
- human animals
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Humanized animals, e.g. knockin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0368—Animal model for inflammation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
Abstract
Se proporcionan animales no humanos que comprenden una secuencia de ácidos nucleicos C3 y/o C5 humanos o humanizados, así como también métodos para usar los mismos para identificar compuestos capaces de modular el sistema del complemento. Se describen animales no humanos que comprenden una sustitución del gen C5 endógeno y/o gen C3 con un gen C5 humano o humanizado, así como métodos para elaborar y usar los animales no humanos. También se proporcionan animales no humanos que comprenden un gen C5 humano o humanizado bajo control de elementos regulatorios C5 no humanos, incluyendo animales no humanos que tienen una sustitución de secuencia de codificación de proteína C5 no humana con secuencia de codificación de proteína C5 humana o humanizada en el locus C5 endógeno no humano. También se proporcionan animales no humanos que comprenden un gen C3 humano o humanizado bajo control de elementos regulatorios C3 no humanos, incluyendo animales no humanos que tienen una sustitución de secuencia de codificación de proteína C3 no humana con secuencia de codificación de proteína C3 humana o humanizada en el locus C3 endógeno no humano. Los animales no humanos que comprenden secuencias C3 y/o C5 humanas o humanizadas, en donde los animales no humanos son roedores, por ejemplo, se proporcionan ratones o ratas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461988581P | 2014-05-05 | 2014-05-05 | |
US201462067836P | 2014-10-23 | 2014-10-23 | |
PCT/US2015/029111 WO2015171523A1 (en) | 2014-05-05 | 2015-05-04 | Humanized c5 and c3 animals |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016014504A true MX2016014504A (es) | 2017-05-23 |
Family
ID=53177902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016014504A MX2016014504A (es) | 2014-05-05 | 2015-05-04 | Animales c5 y c3 humanizados. |
Country Status (15)
Country | Link |
---|---|
US (5) | US9795121B2 (es) |
EP (3) | EP4317445A2 (es) |
JP (1) | JP6598798B2 (es) |
KR (1) | KR102461511B1 (es) |
CN (1) | CN106659146B (es) |
AU (1) | AU2015256299C1 (es) |
BR (1) | BR112016025751A2 (es) |
CA (2) | CA3225091A1 (es) |
ES (1) | ES2779070T3 (es) |
IL (1) | IL248481B (es) |
MA (1) | MA51519A (es) |
MX (1) | MX2016014504A (es) |
RU (2) | RU2020103811A (es) |
SG (2) | SG10202003996YA (es) |
WO (1) | WO2015171523A1 (es) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
MA51519A (fr) | 2014-05-05 | 2020-11-11 | Regeneron Pharma | Animaux c5 et c3 humanisés |
NO2785538T3 (es) | 2014-05-07 | 2018-08-04 | ||
TW202330904A (zh) | 2015-08-04 | 2023-08-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
WO2017132155A1 (en) * | 2016-01-25 | 2017-08-03 | President And Fellows Of Harvard College | Methods and compositions for detecting and treating schizophrenia |
IL309975A (en) | 2016-06-14 | 2024-03-01 | Regeneron Pharma | Antibodies against C5 and their uses |
WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
US10765762B2 (en) | 2017-02-27 | 2020-09-08 | Regeneron Pharmaceuticals, Inc. | Humanized model of kidney and liver disorders |
BR112020000127A2 (pt) | 2017-07-06 | 2020-07-07 | Regeneron Pharmaceuticals, Inc. | método para selecionar um hidrolisado de soja, e, glicoproteína |
CN107736281A (zh) * | 2017-09-29 | 2018-02-27 | 中国水产科学研究院珠江水产研究所 | 一种利用益生菌发酵酱油渣防治池塘养殖鳜鱼寄生虫的方法 |
MX2020003589A (es) * | 2017-09-29 | 2020-07-22 | Regeneron Pharma | Animales no humanos que comprenden un locus ttr humanizado y metodos de uso. |
JP7242650B2 (ja) * | 2017-09-29 | 2023-03-20 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化C1q複合体を発現する非ヒト動物 |
CA3083113A1 (en) | 2017-12-13 | 2019-06-20 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibody combinations and uses thereof |
CN115925882A (zh) | 2017-12-22 | 2023-04-07 | 瑞泽恩制药公司 | 用于表征药物产品杂质的系统和方法 |
BR112020013336A2 (pt) | 2018-01-31 | 2020-12-01 | Regeneron Pharmaceuticals, Inc. | produto farmacêutico proteico, métodos para caracterizar as impurezas do produto farmacêutico proteico de alto peso molecular intermediário, para produção de um anticorpo, e para caracterizar as impurezas de fármaco com variação de carga, anticorpo, e, sistema para caracterizar impurezas de fármaco de alto peso molecular intermediário. |
TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
AU2019227531A1 (en) | 2018-02-28 | 2020-10-15 | Regeneron Pharmaceuticals, Inc. | Systems and methods for identifying viral contaminants |
US11054389B2 (en) | 2018-03-19 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
WO2019195136A1 (en) | 2018-04-03 | 2019-10-10 | Ngm Biopharmaceuticals, Inc. | C3-binding agents and methods of use thereof |
TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
KR20210031868A (ko) | 2018-07-16 | 2021-03-23 | 리제너론 파마슈티칼스 인코포레이티드 | Ditra 질환의 비인간 동물 모델 및 이의 용도 |
SG11202011970TA (en) | 2018-08-27 | 2020-12-30 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
TW202024639A (zh) | 2018-08-30 | 2020-07-01 | 美商再生元醫藥公司 | 用於將蛋白質複合物定特徵之方法 |
AU2020208396A1 (en) | 2019-01-16 | 2021-05-20 | Regeneron Pharmaceuticals, Inc. | Methods for identifying free thiols in proteins |
KR20220004065A (ko) | 2019-04-04 | 2022-01-11 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 응고 인자 12 좌위를 포함하는 비-인간 동물 |
CN114072174A (zh) * | 2019-04-24 | 2022-02-18 | 宾夕法尼亚大学理事会 | 双功能人源化抗c5抗体和因子h融合蛋白以及它们的用途 |
WO2020231992A1 (en) | 2019-05-13 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | Improved competitive ligand binding assays |
JP2022534867A (ja) | 2019-06-04 | 2022-08-04 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ベータスリップ変異を有するヒト化ttr遺伝子座を含む非ヒト動物と使用方法 |
EP3796776A1 (en) | 2019-06-07 | 2021-03-31 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized albumin locus |
CA3150234C (en) | 2019-09-24 | 2023-12-12 | Robert Stairs | Systems and methods for chromatography use and regeneration |
EP4065086A1 (en) | 2019-11-25 | 2022-10-05 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
MX2022008973A (es) | 2020-01-21 | 2022-08-11 | Regeneron Pharma | Metodos de desglicosilacion para electroforesis de proteinas glicosiladas. |
WO2022047108A1 (en) | 2020-08-31 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants |
AU2021352420A1 (en) | 2020-10-01 | 2023-04-27 | Regeneron Pharmaceuticals, Inc. | Rodent animals expressing human cr1 |
JP2023551446A (ja) | 2020-11-25 | 2023-12-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 非水膜乳化を使用した持続放出製剤 |
EP4262757A1 (en) | 2020-12-17 | 2023-10-25 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
KR20230134117A (ko) | 2021-01-20 | 2023-09-20 | 리제너론 파마슈티칼스 인코포레이티드 | 세포 배양물에서 단백질 역가를 개선시키는 방법 |
KR20230150300A (ko) | 2021-03-03 | 2023-10-30 | 리제너론 파마슈티칼스 인코포레이티드 | 단백질 점도를 정량화하고 변경시키기 위한 시스템 및 방법 |
BR112023018665A2 (pt) | 2021-03-26 | 2023-10-03 | Regeneron Pharma | Métodos e sistemas para desenvolvimento de protocolos de mistura |
AU2022286340A1 (en) | 2021-06-01 | 2024-01-04 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
AR127006A1 (es) | 2021-09-08 | 2023-12-06 | Regeneron Pharma | UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc |
AU2022348521A1 (en) | 2021-09-20 | 2024-04-04 | Regeneron Pharmaceuticals, Inc. | Methods of controlling antibody heterogeneity |
AU2022359898A1 (en) | 2021-10-07 | 2024-03-21 | Regeneron Pharmaceuticals, Inc. | Ph meter calibration and correction |
TW202323817A (zh) | 2021-10-07 | 2023-06-16 | 美商再生元醫藥公司 | Ph建模及控制之系統及方法 |
US20230129265A1 (en) | 2021-10-26 | 2023-04-27 | Regeneron Pharmaceuticals, Inc. | Systems and methods for generating laboratory water and distributing laboratory water at different temperatures |
WO2023077053A2 (en) | 2021-10-28 | 2023-05-04 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-related methods and compositions for knocking out c5 |
WO2023177836A1 (en) | 2022-03-18 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Methods and systems for analyzing polypeptide variants |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
WO1984003506A1 (en) | 1983-03-08 | 1984-09-13 | Commw Serum Lab Commission | Antigenically active amino acid sequences |
EP0138854B1 (en) | 1983-03-08 | 1992-11-04 | Chiron Mimotopes Pty. Ltd. | Antigenically active amino acid sequences |
DE3590766C2 (es) | 1985-03-30 | 1991-01-10 | Marc Genf/Geneve Ch Ballivet | |
NZ215865A (en) | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
US5763192A (en) | 1986-11-20 | 1998-06-09 | Ixsys, Incorporated | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
US5266684A (en) | 1988-05-02 | 1993-11-30 | The Reagents Of The University Of California | Peptide mixtures |
US5571689A (en) | 1988-06-16 | 1996-11-05 | Washington University | Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5663143A (en) | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
US5770434A (en) | 1990-09-28 | 1998-06-23 | Ixsys Incorporated | Soluble peptides having constrained, secondary conformation in solution and method of making same |
DE69130831T2 (de) | 1990-11-21 | 1999-09-16 | Iterex Pharma Lp | Synthese äquimolarer mischungen vielzähliger oligomere, speziell oligopeptidmischungen |
DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
US5644048A (en) | 1992-01-10 | 1997-07-01 | Isis Pharmaceuticals, Inc. | Process for preparing phosphorothioate oligonucleotides |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
US6166288A (en) * | 1995-09-27 | 2000-12-26 | Nextran Inc. | Method of producing transgenic animals for xenotransplantation expressing both an enzyme masking or reducing the level of the gal epitope and a complement inhibitor |
GB9521943D0 (en) | 1995-10-26 | 1996-01-03 | Univ Hertfordshire | Coded particles for process sequence tracking in combinatorial compound library preparation |
DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
US6280946B2 (en) | 1998-08-07 | 2001-08-28 | Boston Probes, Inc. | PNA probes, probe sets, methods and kits pertaining to the universal detection of bacteria and eucarya |
EP1141708A1 (en) | 1998-12-28 | 2001-10-10 | Sunesis Pharmaceuticals Inc. | Identifying small organic molecule ligands for binding |
EP1701611B1 (en) * | 2003-12-24 | 2011-05-18 | G2 Inflammation Pty Ltd | Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar |
PT1713503E (pt) | 2004-02-10 | 2013-11-14 | Nat Jewish Health | Inibição do factor b, a via alternativa do complemento e métodos relacionados |
JP5252922B2 (ja) | 2004-10-19 | 2013-07-31 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 遺伝的改変についてホモ接合性の動物を生み出すための方法 |
JP2009523237A (ja) | 2006-01-11 | 2009-06-18 | ノヴォ ノルディスク アクティーゼルスカブ | 改良された球状コード化ビーズ |
MX2010009190A (es) * | 2008-02-20 | 2010-09-10 | G2 Inflammation Pty Ltd | Anticuerpos anti-c5ar humanizados. |
RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
AU2010303737B2 (en) | 2009-10-06 | 2014-05-29 | Institute For Research In Biomedicine (Irb) | Genetically modified mice and engraftment |
RU2730643C2 (ru) | 2011-02-15 | 2020-08-24 | Ридженерон Фармасьютикалз, Инк. | Гуманизированные m-csf мыши |
RS55949B1 (sr) | 2011-10-28 | 2017-09-29 | Regeneron Pharmaeuticals Inc | Humanizovani il-6 i il-6 receptor |
DK3262932T3 (da) | 2011-10-28 | 2019-08-05 | Regeneron Pharma | Genmodificerede mus med major histokompatibilitetskompleks |
US8962913B2 (en) | 2012-06-18 | 2015-02-24 | Regeneron Pharmaceuticals, Inc. | Humanized IL-7 rodents |
NZ741951A (en) | 2012-09-07 | 2020-04-24 | Institute For Res In Biomedicine Irb | Genetically modified non-human animals and methods of use thereof |
CN114766432A (zh) | 2012-11-05 | 2022-07-22 | 再生元制药公司 | 经遗传修饰的非人动物及其使用方法 |
LT2958937T (lt) | 2013-02-22 | 2018-11-26 | Regeneron Pharmaceuticals, Inc. | Pelė, ekspresuojanti humanizuotą audinių dermės kompleksą |
US9155290B2 (en) | 2013-10-15 | 2015-10-13 | Regeneron Pharmaceuticals, Inc. | Humanized IL-15 animals |
EP3071025B1 (en) | 2013-11-19 | 2018-10-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized a proliferation-inducing ligand gene |
MA51519A (fr) | 2014-05-05 | 2020-11-11 | Regeneron Pharma | Animaux c5 et c3 humanisés |
-
2015
- 2015-05-04 MA MA051519A patent/MA51519A/fr unknown
- 2015-05-04 RU RU2020103811A patent/RU2020103811A/ru unknown
- 2015-05-04 EP EP23202404.2A patent/EP4317445A2/en active Pending
- 2015-05-04 BR BR112016025751A patent/BR112016025751A2/pt not_active Application Discontinuation
- 2015-05-04 MX MX2016014504A patent/MX2016014504A/es active IP Right Grant
- 2015-05-04 EP EP19211905.5A patent/EP3636073B1/en active Active
- 2015-05-04 JP JP2016566228A patent/JP6598798B2/ja active Active
- 2015-05-04 ES ES15722639T patent/ES2779070T3/es active Active
- 2015-05-04 US US14/703,818 patent/US9795121B2/en active Active
- 2015-05-04 KR KR1020167032659A patent/KR102461511B1/ko active IP Right Grant
- 2015-05-04 EP EP15722639.0A patent/EP3142483B1/en active Active
- 2015-05-04 CN CN201580034127.8A patent/CN106659146B/zh active Active
- 2015-05-04 RU RU2016146390A patent/RU2713327C2/ru active
- 2015-05-04 SG SG10202003996YA patent/SG10202003996YA/en unknown
- 2015-05-04 CA CA3225091A patent/CA3225091A1/en active Pending
- 2015-05-04 WO PCT/US2015/029111 patent/WO2015171523A1/en active Application Filing
- 2015-05-04 AU AU2015256299A patent/AU2015256299C1/en active Active
- 2015-05-04 CA CA2946412A patent/CA2946412C/en active Active
- 2015-05-04 SG SG11201608696RA patent/SG11201608696RA/en unknown
-
2016
- 2016-10-25 IL IL248481A patent/IL248481B/en active IP Right Grant
-
2017
- 2017-07-26 US US15/660,833 patent/US10492477B2/en active Active
-
2018
- 2018-07-02 US US16/025,377 patent/US10524458B2/en active Active
-
2019
- 2019-10-21 US US16/658,541 patent/US11178860B2/en active Active
-
2021
- 2021-10-20 US US17/505,834 patent/US20220132818A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016014504A (es) | Animales c5 y c3 humanizados. | |
PH12016502058A1 (en) | Humanized il-4 and il-4r alpha animals | |
PH12016502170A1 (en) | Humanized dipeptidyl peptidase iv (dpp4) animals | |
CY1121410T1 (el) | Μη-ανθρωπινα ζωα που εχουν ενα εξανθρωποποιημενο γονιδιο ρυθμιστικης πρωτεϊνης σηματος | |
MX2016016903A (es) | Animales no humanos que tienen un gen de muerte celular programada 1 humanizado. | |
MX2017007636A (es) | Animales no humanos que tienen un gen del grupo de diferenciacion 274 humanizado. | |
MX2017008160A (es) | Inmunomoduladores. | |
MX2017007677A (es) | Inmunomoduladores. | |
MX2018005389A (es) | Animales no humanos que tienen un gen 3 de activacion linfocitaria humanizado. | |
MX2017004542A (es) | Inmunomoduladores. | |
MX2016006513A (es) | Animales no humanos que tienen un gen humanizado de un ligando inductor de la proliferacion. | |
MY183188A (en) | Non-human animals having a humanized b-cell activating factor gene | |
MY172726A (en) | Humanized il-6 and il-6 receptor | |
PH12016501341A1 (en) | Non-human animals having humanized fc-gamma receptors | |
EP3507373A4 (en) | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERAL PD-L1 | |
EP3320773A4 (en) | NON-HUMAN ANIMAL HAVING A CD3 HUMAN GENE SUBSTITUTED WITH ENDOGENOUS CD3 GENE | |
BR112016029076A8 (pt) | Modulação de atividade de complemento | |
EP3222718A4 (en) | Method for knock-in of dna into target region of mammalian genome, and cell | |
BR112017005388A2 (pt) | método para criar animais. | |
MX2019000641A (es) | Composiciones de mucina1-receptor de antigeno quimerico y metodos para su uso. | |
PL3053439T3 (pl) | Kompozycja roztoczy, sposób nanoszenia co najmniej jednej populacji gatunku roztoczy należących do Astigmata w celu zapewnienia źródła pożywienia w uprawie dla roztoczy drapieżnych z Phytoseiidae stosowanych jako biologiczne środki zwalczania | |
MX2021009154A (es) | Selectividad eficaz de proteinas recombinantes. | |
AU2014902950A0 (en) | Composition comprising chondrostereum purpureum for biological control of weedy tree species | |
AU2015901417A0 (en) | An Improved Fishing Sinker | |
UA93605U (uk) | БІС(N-р-ТОЛУЇДАТО ТІОБЕНЗОЙНОЇ КИСЛОТИ)ЦИНКУ, ЯКИЙ ПРОЯВЛЯЄ ВЛАСТИВОСТІ СТИМУЛЯТОРА РОСТУ СІЛЬСЬКОГОСПОДАРСЬКИХ РОСЛИН |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |